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Distinct phosphorylation sites on 
the ghrelin receptor, GHSR1a, 
establish a code that determines 
the functions of ß-arrestins
Monica Bouzo-Lorenzo1,2, Icía Santo-Zas1,2, Maria Lodeiro1, Rubén Nogueiras2,3, Felipe F.  
Casanueva1,2,4, Marian Castro5, Yolanda Pazos1,2, Andrew B Tobin6, Adrian J. Butcher6 & 
Jesús P. Camiña1,2
The growth hormone secretagogue receptor, GHSR1a, mediates the biological activities of ghrelin, 
which includes the secretion of growth hormone, as well as the stimulation of appetite, food intake 
and maintenance of energy homeostasis. Mapping phosphorylation sites on GHSR1a and knowledge of 
how these sites control specific functional consequences unlocks new strategies for the development 
of therapeutic agents targeting individual functions. Herein, we have identified the phosphorylation 
of different sets of sites within GHSR1a which engender distinct functionality of ß-arrestins. More 
specifically, the Ser362, Ser363 and Thr366 residues at the carboxyl-terminal tail were primarily responsible 
for ß-arrestin 1 and 2 binding, internalization and ß-arrestin-mediated proliferation and adipogenesis. 
The Thr350 and Ser349 are not necessary for ß-arrestin recruitment, but are involved in the stabilization 
of the GHSR1a-ß-arrestin complex in a manner that determines the ultimate cellular consequences of 
ß-arrestin signaling. We further demonstrated that the mitogenic and adipogenic effect of ghrelin were 
mainly dependent on the ß-arrestin bound to the phosphorylated GHSR1a. In contrast, the ghrelin 
function on GH secretion was entirely mediated by G protein signaling. Our data is consistent with the 
hypothesis that the phosphorylation pattern on the C terminus of GHSR1a determines the signaling and 
physiological output.
The growth hormone secretagogue receptor type 1a (GHSR1a), a receptor belonging to the diverse group of seven 
transmembrane receptors, critically regulates the central and peripheral actions of ghrelin as a growth hormone 
secretagogue, an orexigenic peptide, and a long-term regulator of energy homeostasis1. Ghrelin is a 28-amino 
acid residue peptide with a post-translational octanoyl modification on Ser3, which was first discovered in rat and 
human stomach tissues2. This hormone is mainly synthesized in the stomach, but substantially lower amounts 
have been detected in other tissues3,4. GHSR1a is expressed in several brain areas, including the anterior pituitary 
gland where it stimulates the release of growth hormone (GH)2,5 as well as the hippocampus and hypothalamic 
arcuate nucleus where it regulates feeding behavior6,7, and the substantia nigra pars compacta, ventral tegmental 
area and raphe nuclei where GHSR1a controls the mesolimbic dopaminergic reward circuit1,8. At peripheral level 
GHSR1a is expressed in pancreatic islets, adrenal gland, thyroid, myocardium, and adipose tissue. Numerous 
peripheral actions of ghrelin have been described which include regulation of glucose metabolism, lipogenesis, 
suppression of brown fat thermogenesis and improvement of cardiovascular functions such as vasodilatation and 
cardiac contractility1.
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GHSR1a classically exerts intracellular effects through G-protein activation, mainly via Gq/11 and Gi/o9,10. 
However, recent evidence has demonstrated that ß-arrestins act as molecular mediators of G-protein independent 
signaling by acting to scaffold a variety of signaling proteins11–14. Initially, described as contributing to desensiti-
zation of GHSR1a through the regulation of the endocytosis15 ß-arrestins are now known contribute to GHSR1a 
signal transduction via ERK1/2-mitogen-activated protein kinase11 and Akt/protein kinase B12–14 signaling path-
ways. The signaling mechanisms that underlie the activation of the ERK response by GHSR1a are complex and 
the result of both classical G protein signaling and ß-arrestin–dependent processes12. The G protein component of 
this response involves Gi/o-dependent signaling upstream of phosphatidylinositol 3-kinase (PI3K), protein kinase 
Cε , and the non-receptor tyrosine kinase cSrc as well as Gq/11-dependent signaling involving the activation of pro-
tein kinase Cα /ß and cSrc. These G protein-dependent mechanisms operate in concert with GHSR1a mediated 
ß-arrestin signaling that lies up-stream of cSrc, Raf-1, and ERK1/2.
In addition, GHSR1a activates Akt signaling through a complex interplay of distinct signaling mechanisms: an 
early Gi/o protein–dependent pathway and a late pathway mediated by ß-arrestins. The early Gi/o protein–depend-
ent pathway involves PI3K activation that leads to the membrane recruitment and activation of Akt. The later 
phase of Akt activation is dependent on ß-arrestins 1 and 2 and involves the recruitment of cSrc and Akt into a 
complex. This ß-arrestin-scaffolded complex leads to full activation of Akt through PDK1 and mTORC2, which 
are not physically associated to the complex. Whether GHSR1a activates Akt through the G protein pathway or 
the ß-arrestin-dependent pathway is determined by cSrc, which functions as a switch. This switch operates by 
cSrc phosphorylating the C-terminus of SHP-1 (Tyr536), which results in an inhibitory effect on Gi/o protein 
activation of Akt by inhibiting the activity of PI3K12,13.
Recently we have established the importance of ß-arrestin-mediated signaling in functional ghrelin/GHSR1a 
responses. In particular, adipogenic functions of the ghrelin/GHSR1a system have been linked with ß-arrestin 
signaling. In these studies ß-arrestin depletion during ghrelin-induced adipogenesis reduced C/EBPß, C/EBPδ , 
C/EBPα and PPARγ levels, leading to a significant reduction of lipid accumulation and to the impairment of 
terminal differentiation14.
Thus, it is becoming increasingly evident that ß-arrestins, originally discovered as mere adaptor proteins 
for the GHSR1a endocytosis, have much broader signaling and physiological roles. What is not clear however 
are the factors that regulate GHSR1a coupling to ß-arrestin-dependent signaling and the processes that regu-
late the relative contribution of G-protein versus ß-arrestin-dependent signaling. It is now well established that 
GPCR phosphorylation plays a crucial role in the recruitment and activation of ß-arrestin-dependent signal-
ing. Recent studies have gone further and suggested that the pattern of phosphorylation on a GPCR constitutes 
a barcode that determines, at least in part, the signaling outcomes16–20. The possibility that GHSR1a regulates 
ß-arrestin-dependent signaling through a phosphorylation barcode, has, however, not been investigated. Here 
we determine the phosphorylation sites on GHSR1a and show that these are arranged into two distinct clusters 
on the C terminus of the receptor. By analysis of the impact that GHSR1a phosphorylation has on various sign-
aling and cellular responses we provide evidence of a phosphorylation barcode that instructs the recruitment of 
ß-arrestin and determines GHSR1a functionality.
Results
Identification of phosphorylation sites in GHSR1a by mass spectrometry. Following stimulation 
with ghrelin (100 nM, 5 min), phosphorylation of GHSR1a was enhanced as monitored by increased incorpora-
tion of 32P into a protein with an apparent molecular mass ∼ 100 KDa (~2.8 ± 0.2-fold; Fig. 1A). To identify the 
precise phosphorylation sites, a mass spectrometry-based proteomics study of tryptic peptides generated from 
the isolated GHSR1a was conducted (Fig. 1B–E). These studies revealed 3 serine (Ser349, Ser362 and Ser363 and 2 
threonine (Thr350 and Thr366) phospho-acceptor sites at the C-terminal tail. The tryptic peptides generated by 
digestion of GHSR1a included peptides originating from the third intracellular loop, however, there was no indi-
cation that any of the peptides from this region were phosphorylated. HEK cells stably expressing GHSR1a were 
generated in which these phosphorylation sites were mutated to Ala residues. In a double mutant of GHSR1a, des-
ignated GHSR1a-DM, in which Thr350 and Ser349 were mutated to Ala, phosphorylation in response to ghrelin was 
reduced by 57± 3% (Fig. 2B). Triple mutation of GHSR1a, designated GHSR1a-TM, in which Ser362, Ser363and 
Thr366 were mutated to Ala, phosphorylation was reduced by 58± 2% (Fig. 2B). A further mutant was generated 
in which all of the residues identified by mass spectrometry to be phosphorylated were substituted by Ala (Ser349, 
Ser362, Ser363, Thr350 and Thr366), and was designated GHSR1a-Total. The phosphorylation status of GHSR1a-Total 
was significantly less than that of either GHSR1a-DM or GHSR1a-TM indicating that the sites of ghrelin-regu-
lated phosphorylation in the GHSR1a were mainly Ser349, Ser362, Ser363 Thr350 and Thr366.
Phosphorylation of the C-terminal tail of the GHSR1a regulates receptor endocytosis and 
ß-arrestin 1 and 2 recruitment. To determine the importance of the receptor C-termini phosphorylation 
in directing specific signaling events, we first compared ghrelin-induced receptor endocytosis (100 nM) by con-
focal microscopy in HEK 293 cells expressing GHSR1a-WT or GHSR1a mutants. In the resting cells, fluorescence 
associated with the receptor was predominantly localised to the plasma membrane (Fig. 2C). A slight fluores-
cence was also associated with the Golgi apparatus, even after treatment with cycloheximide. After exposure to 
ghrelin for 20 and 60 minutes, the GHSR1a-WT-associated fluorescence almost completely disappeared from 
the plasma membrane to become redistributed to a population of intracellular vesicles distributed throughout 
the cytoplasm (Fig. 2C). In cells expressing GHSR1a-DM, the receptor was primarily distributed throughout the 
cytoplasm after 20 and 60 minutes of agonist treatment although the population of intracellular vesicles appeared 
to be reduced (Fig. 2C). By contrast, very little redistribution of the fluorescent labeling could be observed in 
cells expressing GHSR1a-TM or GHSR1a-Total after 20 minutes and even after 60 minutes of agonist treatment 
(Fig. 2C). In order to determine whether this change in the patterns of endocytosis displayed by the mutant 
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receptors was due to differences in their ability to interact with ß-arrestins, cells were transiently co-transfected 
with RFP-tagged ß-arrestin 1 or m-cherry-tagged ß-arrestin 2. As shown in Fig. 3A,B, the receptors (shown in 
green) were located at the cell surface, whereas RFP-ß-arrestin 1 or m-cherry-ß-arrestin 2 was uniformly distrib-
uted in the cytoplasm in unstimulated cells (shown in red). In response to 20-minute stimulation with ghrelin 
(100 nM), GHSR1a-WT appeared to colocalize with both ß-arrestin 1 and 2 in endocytic vesicles (shown in 
yellow; Fig. 3A,B). This colocalization is consistent with the assembly of a protein complex containing ß-arrestin 
and the receptor and appeared to be more robust after 60 minutes of agonist treatment. Similarly, stimulation 
of GHSR1a-DM induced colocalization of the receptor with both ß-arrestins (Fig. 3A,C). However, this colo-
calization was rather more evenly distributed in the cytoplasm in a diffuse granular pattern, with no apparent 
enhancement of localization in endocytic vesicles. In contrast, in the case of GHSR1a-TM and GHSR1a-Total, the 
receptors remained localized at plasma membrane whilst ß-arrestin remained evenly distributed in the cytoplasm 
after agonist stimulation (Fig. 3A,C). An examination of two of the coefficients used to quantify the degree of 
colocalization between fluorophores, the Pearson correlation coefficient (PCC) and the Mander’s overlap coeffi-
cient (MOC), supported the assembly of a protein complex containing ß-arrestin and GHSR1a or GHSR1a-DM, 
and ruled out a complex for GHSR1a-TM or GHSR1a-Total (Fig. 3B,D). To examine in more detail the contribu-
tions of agonist dependent phosphorylation in the C-terminal tail of GHSR1a to recruitment of ß-arrestin 1 and 
2, BRET assays were performed which enabled association of an eYFP tagged GHSR1a and an Rluc-ß-arrestin to 
be measured in real time in living cells (Fig. 4A,B, respectively). GHSR1a-WT recruited both ß-arrestin 1 and 2 in 
an agonist dependent manner. Concentration response curves for ß-arrestin 1 recruitment to each receptor were 
determined, which revealed that the GHSR1a-DM and GHSR1a-TM showed a subtle but significant decrease in 
Figure 1. Mass spectrometry identifies five distinct sites of phosphorylation in the GHSR1a. HEK 293 
cells transiently expressing C-terminally EGFP-tagged GHSR1a were either labeled with 32P (A) or used to 
immunoprecipitate and then digest the receptor for analysis using mass spectrometry (C–E). In the 32P labeling 
studies, cells were treated with the agonist ghrelin (100 nM) or vehicle for 5 min prior to sample preparation. 
(A) Left panel, autoradiograph and loading control (EGFP immunoblot) is shown. Right panel, levels of 32P were 
quantified by densitometry, normalized to GHSR1a-EGFP, and expressed as fold increase relative to the control 
cells. Immunoblot is representative of five independent experiments. The data are expressed as the mean ± SE 
(*p < 0.05). (B) Amino acid sequence of the GHSR1a indicating in red the amino acids identified as being 
phosphorylated. (C–E) representative mass spectra and associated fragmentation tables are shown for the five 
phosphorylated amino acid residues, three serine (Ser349, Ser362 and S363) and 2 threonine (Thr350 and Thr366), 
which were identified. Green text denotes amino acid residues identified from eGFP. (F) Summary of the overall 
data set.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:22495 | DOI: 10.1038/srep22495
potency compared to GHSR1a-WT (GHSR1a-WT, pEC50 = 7.54; GHSR1a-DM, pEC50 = 7.10; and, GHSR1a-TM, 
pEC50 = 7.13; p < 0.05). The GHSR1a-Total mutant showed the greatest reduction in potency, which was substan-
tially decreased, compared to GHSR1a-DM (pEC50 = 6.01). In addition, there was a significant reduction in effi-
cacy (GHSR1a-DM = 81.3%, GHSR1a-TM = 36.8%, GHSR1a-Total = 31.8% of GHSR1a-WT response; p < 0.05). 
In the case of ß-arrestin 2, a significant decrease in both potency (GHSR1a-WT, pEC50 = 7.30, GHSR1a-DM, 
pEC50 = 7.14; GHSR1a-TM pEC50 = 6.97; and, GHSR1a-Total pEC50 = 6.04; p < 0.05) and efficacy was also 
observed (GHSR1a-DM = 82.4%, GHSR1a-TM = 24.6%, GHSR1a-Total = 18.0% of GHSR1a-WT response; 
p < 0.05). These observations are consistent with the absence of receptor/ß-arrestin colocalization observed by 
confocal analysis. The BRET values for ß-arrestin 2 recruitment to GHSR1a-WT were greater than those for 
ß-arrestin 1, which might reflect differences in the receptor/ß-arrestin conformation resulting in a greater dis-
tance between the luciferase and YFP tags or difference in affinity of both ß-arrestins.
To gain further insight into the role of receptor phosphorylation in regulating ß-arrestin recruitment, we 
monitored BRET as a function of the acceptor/donor ratio (eYFP-receptor/luciferase-ß-arrestin) and deter-
mined the acceptor-donor ratio at which half-maximal BRET (BRET50) is observed (Fig. 3E,F). BRET50 values for 
GHSR1a-DM/ß-arrestin interactions were higher than those for GHSR1a-WT, suggesting that GHSR1a-WT has 
a higher relative affinity for both ß-arrestins than GHSR1a-DM. The BRETmax value was also decreased, indicating 
that the nature of the receptor/ß-arrestin interactions were different such that the acceptor and donor tags were in 
closer proximity with the GHSR1a-WT. These data might suggest that the binding of ß-arrestins to the GHSR1a 
involves two separate sets of interactions with the phosphorylated carboxyl-terminus of the receptor, one with 
Figure 2. Mutational analysis of GHSR1a on ghrelin-induced phosphorylation and endocytosis. (A) Schematic 
representation of the C-terminal portion of GHSR1a showing the Ser and Thr residues that were found to be 
phosphorylated and that were subsequently mutated to alanine to generate GHSR1a-DM, GHSR1a-TM and 
GHSR1a-Total mutants. The mutated residues are shown in red. (B) Left panel, 32P labeling studies were performed 
using HEK 293 cells transiently expressing either the EGFP-tagged GHSR1a-WT or the mutants. Right panel, levels 
of 32P were quantified by densitometry, normalized to GHSR1a-EGFP, and expressed as fold increase relative to the 
control cells expressing the GHSR1a-WT. Immunoblots are representative of five independent experiments. The 
data are expressed as the mean ± SEM (*,#p < 0.05). (C) Analysis of GHSR1a endocytosis by confocal microscopy. 
EGFP-tagged GHSR1a-WT or C-terminal tail Ala mutants were transiently expressed in HEK 293 cells and 
stimulated with ghrelin (100 nM) for stated times at 37 °C. In absence of ligand, the fluorescent labeling appeared 
at the cell surface for the GHSR1a-WT and mutants. After a 20 and 60 minutes stimulation with ghrelin, the 
extent of receptor endocytosis is substantially reduced in the GHSR1a-DM, GHSR1a-TM and GHSR1a-Total 
mutants compared to the GHSR1a-WT (lower panel). Confocal images are representative of three independent 
experiments. The data are expressed as the mean ± SEM (*,#p < 0.05).
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the phosphorylation sites Ser362, Ser363and Thr366 that serve as essential phosphate recognition elements for the 
ß-arrestin recruitment, and the other with the phosphorylation sites Thr350 and Ser349 that might stabilize active 
conformation of ß-arrestins.
ß-arrestin signaling is determined by the phosphorylation of the C-terminal tail of the GHSR1a: 
ERK1/2 and Akt activation. The role of the two phospho-acceptor regions at the GHSR1a C-terminal 
tail (Ser362, Ser363 and Thr366, or Thr350 and Ser349) was first evaluated on ghrelin-induced phosphorylation of 
ERK1/2 [pERK1/2(T202/Y204)] by transient transfection of GHSR1a-WT, GHSR1a-DM and GHSR1a-TM 
in HEK 293 cells. In GHSR1a-WT cells stimulated with ghrelin (100 nM), pERK1/2(T202/Y204) was resolved 
into two components dependent, respectively, on G protein or ß-arrestin signaling as we previously described11. 
G protein-dependent activity was rapid, peaking within ~5 min, followed by a ß-arrestin-dependent acti-
vation that was slower in onset, peak ~20 min, and sustained (Fig. 5A). This sustained pERK1/2(T202/Y204) 
signal declined with C-terminal tail mutations GHSR1a-DM and GHSR1a-TM, whilst the fast and transient G 
protein-dependent activation was maintained. The decrease in the ERK1/2 activation correlated with the decline 
of the receptor/ß-arrestin signaling complex formation (Fig. 5A).
These mechanistic differences were confirmed in three types of MEF cells: MEF cells from wild-type mice 
(MEF WT), MEF cells from ß-arrestin1 null mice (ß-arrestin 1−/−) and MEF cells from ß-arrestin 2 null mice 
(ß-arrestin 2−/−) (Fig. 5B). In the MEF WT cells expressing GHSR1a, stimulation with ghrelin led to an early 
peak phase of ERK activation followed by a sustained plateau phase (Fig. 5B). Whilst the peak ERK activation in 
Figure 3. The phospho-acceptor residues in C-terminal tail of GHSR1a-WT govern both binding and 
trafficking patterns of ß-arrestins. (A) Trafficking of the RFP-tagged ß-arrestin 1 with the EGFP-tagged 
GHSR1a-WT or the mutants GHSR1a DM, GHSR1a -TM or GHSR1a TOTAL expressed in HEK 293 cells. 
(B) Correlation measurements between RFP-tagged ß-arrestin 1 with the EGFP-tagged GHSR1a-WT or the 
mutants were made on a single cell using two coefficients: the PCC and MOC. (C) Trafficking of the m-cherry-
tagged ß-arrestin 2 with the EGFP-tagged GHSR1a-WT or the mutants GHSR1a DM, GHSR1a -TM or 
GHSR1a Total expressed in HEK 293 cells. (D) PCC and MOC correlation coefficients were evaluated as the 
measurement of colocalization between m-cherry-tagged ß-arrestin 2 with the EGFP-tagged GHSR1a-WT 
or the mutants. In (A,C) confocal images show the localization of the ß-arrestin and the GHSR1a before and 
following stimulation with ghrelin (100 nM) for 20 or 60 minutes. Receptor fluorescence is shown in green and 
ß-arrestin fluorescence in red. Co-localisation of ß-arrestin and the receptor is shown in yellow when images 
are merged. Results are representative of three similar experiments. In (B,C) The data are expressed as the 
mean ± SEM.
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response to GHSR1a stimulation in MEF ß-arrestin 1−/− and 2−/− cells was unchanged compared to WT-MEFs, 
the sustained plateau phase was lost indicating that the plateau phase of the ERK response to GHSR1a was 
ß-arrestin-dependent. Consistent with this was the observation that expression of the GHSR1a-TM which 
recruits ß-arrestin poorly resulted in a significant decrease in the plateau phase compared to the wild type 
GHSR1a and to the mutant GHSR1a-DM, which showed relatively robust coupling to ß-arrestin (Fig. 5B).
We next sought to determine the functional consequences of phosphorylation/ß-arrestin-dependent 
ERK1/2 activation by the analysis of the mitogenic activity associated with the GHSR1a mutants in HEK 293 
cells. Whereas ghrelin-treated GHSR1a-WT cells (100 nM) incorporated BrdU at a ~2-fold over control, cells 
expressing GHSR1a-DM or GHSR1a-TM failed to incorporate BrdU (Fig. 5D). Whereas the results obtained 
with the GHSR1a-TM mutant excludes the role of G protein-dependent signaling on ghrelin-activated prolifer-
ation, the lack of GHSR1a-DM mitogenic effect might be related to the stabilization of the active conformation 
of ß-arrestins exerting spatial control over MAPK events. We therefore examined the subcellular location of 
pERK1/2(T202/Y204) in cells expressing GHSR1a-WT and GHSR1a-DM EGFP-tagged receptors after ghre-
lin stimulation (100 nM) by confocal microscopy. In cells expressing GHSR1a-DM, pERK1/2(T202/Y204) was 
primarily observed in the cytoplasm after activation, whereas in cells expressing GHSR1a-WT, most of the 
pERK1/2(T202/Y204) translocated into the nucleus (Fig. 5C). Thus, the phospho-acceptor sites at the GHSR1a 
C-terminal tail appeared to influence the ultimate cellular consequence of ß-arrestin recruitment.
The model for the activation of Akt by ghrelin involves the interplay of an early Gi/o protein-dependent 
pathway and a late pathway mediated by ß-arrestins12,13. Certainly, in HEK 293 cells transiently transfected 
with the GHSR1a-WT ghrelin (100 nM), ghrelin-activated pAkt (S473) (100 nM) was resolved into two com-
ponents: an initial rapid G protein-dependent activation which peaks within ∼ 10 min, this is followed by 
a ß-arrestin-dependent activation which is sustained over time (Fig. 6A). This sustained pAkt(S473) signal 
decreased with C-terminal tail mutations GHSR1a-DM and GHSR1a-TM, correlating with the decline of the 
receptor/ß-arrestin signaling complex formation, this effect was also observed in MEF ß-arrestin 1−/− and 2−/− 
cells (Fig. 6B). To determine the importance of the GHSR1a C termini in directing specific Akt signaling events, 
the effects of siRNA-mediated suppression of ß-arrestins were examined on the ghrelin-induced intracellular 
lipid storage in 3T3-L1 cells. This approach was chosen based on the endogenous GHSR1a expression in either 
undifferentiated (preadipocytes) or differentiated 3T3-L1 (adipocytes), which would make it difficult to discern 
the differences among GHSR1a mutants. Thus, 3T3-L1 preadipocyte cells were induced to differentiate into adi-
pocytes using a standard adipogenic induction cocktail of IBMX, DEX and ghrelin for 72 h (early differentiation), 
followed by suppression of ß-arrestin 1 and 2 with specific siRNAs during terminal differentiation. Oil Red O 
staining was performed to monitor intracellular ghrelin-induced lipid storage at day 6 after the initiation of dif-
ferentiation. Efficiency of ß-arrestin 1 and 2 siRNA depletion was confirmed by immunoblot analysis after dif-
ferentiation (65 ± 5% and 69 ± 2%, respectively). For the ghrelin-induced adipogenesis, depletion of ß-arrestin 1 
or 2 caused a substantial inhibition of fat droplet accumulation when compared to siRNA control (61 ± 13% and 
73 ± 16%, respectively; Fig. 6C). The ß-arrestin signal complex determines the adipogenic functions of ghrelin 
highlighting the importance of the phospho-acceptor sites at the GHSR1a C-terminal tail as molecular determi-
nants for the formation of the receptor/ß-arrestin complex and the ultimate signaling outcomes.
Figure 4. BRET approach to monitor the ß-arrestin interactions with the GHSR1a. GHSR1a-WT and each 
mutant were used in a BRET based ß-arrestin recruitment assay in HEK 293 cells. Concentration response 
curves for ghrelin to promote the interaction of GHSR1a with ß-arrestin 1 (A) or ß-arrestin 2 (B) are shown. 
(C) HEK 293 cells were transfected with a constant amount of ß-arrestin1 and increasing amounts of YFP-
GHSR1a-WT or YFP-GHSR1a-DM (acceptors) and treated with ghrelin. Net BRET is expressed as a function of 
acceptor/donor. (D) Titration curves monitoring net BRET in response to varying acceptor/donor ratios were 
performed as in (C). In (C,D) BRET50 and BRETmax values calculated from three independent experiments.
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Gq/11 activity of ghrelin is not related to the phosphorylation of the C-terminal tail of the 
GHSR1a. Upon activation, GHSR1a carries information within the cell via a transient increase of intracellu-
lar Ca2+ through the generation of inositol 1,4,5-triphosphate (IP3) triggered by protein subunit Gαq/119. Because 
the lifetime of IP3 is extremely short, Gαq/11-dependent GHSR1a activation can be followed by monitoring IP3 
degradation products, such as inositol 1-phosphate (IP1), which accumulates in the cell in the presence of lithium 
chloride. As shown in Fig. 7A, HEK 293 cells transiently expressing the C-terminal tail mutations, GHSR1a-DM, 
and GHSR1a-TM, revealed similar IP1 accumulation in relation to GHSR1a-WT in response to ghrelin (100 nM). 
It is well established that the GHSR-1a stimulates GH release through intracellular Ca2+ concentration via IP3. 
To further investigate the role of the GHSR1a phosphorylation sites and ß-arrestin signaling, we tested the effect 
siRNA knockdown of ß-arrestins on the GH release in GC cells. As with 3T3-L1 cells, this approach was selected 
based on the endogenous GHSR1a expression in GC cells. Transfection of the cells with siRNAs directed against 
ß-arrestin 1 or 2, which decreased ß-arrestin 1 and 2 expression by 50 ± 1% and 80 ± 3% respectively, did not 
significantly alter ghrelin-activated GH release compared to cells treated with control siRNA (Fig. 7B). These 
results demonstrate the contribution of individual G protein and ß-arrestin pathways in the GHSR1a signaling.
Figure 5. Functional relation between the GHSR1a-associated ß-arrestin-scaffolded complex and the 
ERK1/2 activity. (A) HEK 293 cells were transiently transfected with GHSR1a-WT or mutants and stimulated 
with ghrelin (100 nM) for the indicated times. Samples of cell lysates were separated by SDS PAGE and 
immunoblots were performed using anti pERK1/2(T202/Y204) or anti total ERK1/2 antibodies. The levels of 
pERK1/2were quantified by densitometry, normalized to total ERK1/2 and expressed as the fold change relative 
to the unstimulated cells. (B) The MEF WT, ß-arrestin 1−/− and ß-arrestin 2−/− cells were treated as in (A). The 
levels of pERK1/2(T202/Y204) were expressed as the fold change relative to the unstimulated cells. In (A,B) 
immunoblots are representative of three independent experiments, the data are expressed as the mean ± SEM. 
(C) HEK 293 cells expressing GHSR1a-WT and GHSR1a-DM were stimulated with ghrelin for indicated time 
before being fixed and stained with anti pERK1/2(T202/Y204) antibodies, images were acquired by confocal 
microscopy. DAPI was used as a counterstain to identify nuclei and is shown in blue. Confocal images are 
representative of three independent experiments. (D) Mitogenic effect of ghrelin (100 nM) on cells transiently 
transfected with the GHSR1a-WT or mutants (n = 6). Results were expressed as a fold increase in BrDU 
incorporation relative to control cells. The data are expressed as the mean ± SEM (*,#p < 0.05).
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Discussion
In the present study we used mass spectrometry-based proteomic approach to map five phosphorylation sites that 
can be divided into 2 regions, region 1 (Thr350 and Ser349) and region 2 (Ser362, Ser363 and Thr366). These regions 
appear to contribute equally to the overall phosphorylation of the receptor. However we found that the region 2 
was primarily responsible for ß-arrestin 1 and 2 binding, receptor internalization, ß-arrestin-mediated ERK and 
Akt activation. In contrast, region 1 appeared to play a more subtle role of stabilizing the interaction between the 
receptor and ß-arrestins. In this way our data suggest a differential impact of phosphorylation sites on ß-arrestin 
recruitment and ß-arrestin-dependent signaling and is consistent with a model in which different phosphoryl-
ation pattern (barcode) on the GHSR1a can induce distinct ß-arrestin interactions that determine the ultimate 
cellular consequences of ß-arrestin signaling.
An intriguing observation was the fact that mutation of the phosphorylation sites Thr350 and Ser349, 
GHSR1a-DM, subtly reduced the potency and efficacy of ß-arrestin binding, which might suggest the implication 
of these phosphorylation elements in the fine-tune of their interactions with the GHSR1a. This modifying role 
of region 1 on responses such as internalization appeared to be a unique feature of this study. Phosphorylation 
within region 2 primarily mediated ß-arrestin recruitment and receptor internalization as revealed by the 
mutant GHSR1a-TM, analysis of ß-arrestin interactions with the region 1 mutant, GHSR1a-DM, determined 
that ß-arrestin 1 and 2 are both recruited to this mutant receptor but with a lower apparent affinity. These data 
Figure 6. Functional relation between the GHSR1a-associated ß-arrestin-scaffolded complex and the Akt 
activity. (A) HEK 293 cells were transiently transfected with GHSR1a-WT or mutants and stimulated with 
ghrelin (100 nM) for the indicated times. Samples of cell lysates were separated by SDS PAGE and immunoblots 
were performed using anti pAkt (S473) or total Akt antibodies. The levels of pAkt (S473) were quantified by 
densitometry, normalized to total Akt, and expressed as the fold change relative to the unstimulated cells.  
(B) The MEF WT, ß-arrestin 1−/− and ß-arrestin 2−/− cells treated as in (A) and the levels of pAkt (S473) were 
expressed as the fold change relative to the unstimulated cells. In (A,B) immunoblots are representative of three 
independent experiments and data are expressed as the mean ± SEM. (C) Effect of siRNA depletion of ß-arrestins 
on terminal adipogenesis in 3T3-L1 cells. After induction for 3 days under treatment with IBMX (0.5 mM), DEX 
(25 μM), and ghrelin (861 nM) in DMEM/10% FBS, the cells were transfected with specific ß-arrestin 1 or 2 
siRNAs and maintained for 3 days in the presence of ghrelin (172 nM) in DMEM/10% FBS. The cells were stained 
with Oil red O and the lipid droplet accumulation was analyzed using the spectrophotometric absorbance at 
520 nm. The results are expressed as the fold change in lipid accumulation relative to the differentiated controls.
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suggest that although phosphorylation of Ser362, Ser363 and Thr366 can promote ß-arrestin recruitment with the 
GHSR1a, it is phosphorylation of Thr350 and Ser349 that is required to stabilize the interaction between the recep-
tor and ß-arrestin. That this stabilization might have functional significance was evidenced by the lack of nuclear 
translocation of ERK1/2 and cell proliferation observed for the GHSR1a-DM. Importantly, previous studies have 
determined these GHSR1a functional responses to be dependent on ß-arrestin signaling11. Since differences in 
GPCR-mediated ERK nuclear signaling have previously been linked to the stability of the receptor:ß-arrestin 
complex21–23, it is possible to speculate that the phosphorylation barcode (particularly phosphorylation within 
region 1) on GHSR1a contributes to the stability of the GHSR1a:ß-arrestin complex in a manner that impacts on 
ERK nuclear signaling16,24,25.
How might phosphorylation mediate changes in the affinity and stability of the GHSR1a:ß-arrestin complex is 
not currently clear; however, recent studies using a ß-arrestin biosensor to detect gross changes in conformation 
suggest phosphorylation of the different sets of sites engenders the distinct functionality of ß-arrestin by inducing 
different conformations of the receptor-bound ß-arrestin16,24. These findings are consistent with a model where 
the patterning of receptor phosphorylation sites establishes a code that determines the conformation of the bound 
ß-arrestins and subsequently its functional capabilities. Thus, differences in ß-arrestin binding in response to 
recruitment to GHSR1a versus GHSR1a-DM might underlie the differences in signaling we observed.
The interaction between ß-arrestin and activated GPCRs is proposed to involve a biphasic mechanism26–28. 
The first step comprises an interaction between the phosphorylated C-terminal tail of the receptor and the 
N-terminal domain of arrestin followed by the insertion of the finger loop of ß-arrestin within the receptor core 
that engages additional binding sites resulting in a longitudinal arrangement on the receptor. Following this 
model, the phospho-acceptor sites operate in concert with structural elements within the transmembrane core 
of the receptor. Indeed, recent studies demonstrated that mutations of the contiguous conserved amino acids 
Pro148 and Leu149 in the GHSR1a intracellular second loop generate receptors with a strong bias to G protein and 
ß-arrestin respectively, supporting a role for conformation-dependent signaling bias in the wild-type receptor29. 
Thus, the nature of the active conformation of ß-arrestin and the signaling outcome is determined by the com-
plex ensemble of the GHSR1a phosphorylation sites within the C-terminal tail in combination with structural 
elements within intracellular loops that confer the functional selectivity.
An interesting aspect is the functional selectivity associated with the differential GHSR1a-stimulated G 
protein- and ß-arrestin-mediated signaling to control particular cellular response. Our findings from ß-arrestin 
knockdown indicates the GH-releasing activity results from G protein signaling with no implication of ß-arrestin 
signaling because this action occurs upon activation of ß-arrestin-impaired GHSR1a. Following the mutation of 
phospho-acceptor sites, the proliferative effect of ghrelin was impaired implicating ß-arrestin-mediated ERK1/2 
pathway in this response. Furthermore, the ß-arrestin-scaffolded complex positively determines Akt activity and 
adipocyte differentiation. We have previously demonstrated the importance of these scaffolding proteins during 
ghrelin-induced adipogenesis in 3T3-L1 cells, which determined the expression levels of master regulators of 
early, the CCAAT/enhancer-binding protein ß (C/EBPß) and the CCAAT/enhancer-binding protein δ (C/EBPδ ), 
and terminal, the peroxisome proliferator-activated receptor (PPARγ ) and the CCAAT/enhancer-binding pro-
tein α (C/EBPα ), adipogenesis14. Initially, these findings imply the existence of independent G protein- and 
Figure 7. The functionality of Gq/11-protein mediated GHSR1a signaling is independent of receptor 
phosphorylation and ß-arrestin binding. (A) Determination of ghrelin-induced IP1 accumulation in HEK 293 
cells transiently transfected with the GHSR1a-WT or mutants. The levels of accumulated IP1 were expressed 
as the fold change relative to the unstimulated GHSR1a-WT cells. Data points correspond to means ± SEM 
of three experiments performed in triplicate. (B) The effect of ghrelin (100 nM) on the GH release in GC cells, 
transiently transfected with the GHSR1a-WT in the absence or presence of ß-arrestin siRNAs. GH release was 
estimated by ELISA. Samples of cell lysates were separated by SDS PAGE and immunoblots probed with anti 
ß-arrestin 1, anti ß-arrestin 2 or anti actin antibodies. The levels of ß-arrestins and actin were quantified by 
densitometry, normalized to total actin, and expressed as fold relative to the siRNA control. Immunoblots are 
representative of three independent experiments. The data are expressed as the mean ± SEM (*p < 0.05).
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ß-arrestin-mediated pathways. However, this does not appear to be the case since ß-arrestin signaling is depend-
ent on the G protein activation11,12. This fact suggests that certain key components of the G protein-dependent 
signaling pathways are required to determine ß-arrestin recruitment and signaling. In fact, our previous works 
demonstrated that ghrelin leads to the activation of Akt through an early Gi/o-protein-dependent pathway and a 
late pathway mediated by ß-arrestins12–14. The starting point is the Gi/o-protein dependent PI3K activation that 
leads to the membrane recruitment of Akt, which becomes tyrosine phosphorylated by c-Src with the subsequent 
phosphorylation in both the activation loop within the kinase domain [A-loop (T308)] and the hydrophobic 
motif in the C-terminal region [HM (S473)] by PDK1 and mTORC2, respectively. Once the receptor is activated, 
a second signaling pathway is mediated by ß-arrestin 1 and 2, involving the recruitment of ß-arrestins, c-Src and 
Akt. This ß-arrestin-scaffolded complex leads to full activation of Akt. In agreement with these results, assays 
performed in 3T3-L1 preadipocyte cells indicate that ß-arrestins and c-Src are implicated in the activation of Akt 
in response to ghrelin through the GHSR1a12,13. These results support the notion that key components of the G 
protein-dependent signaling pathways, such as Gi/o-protein dependent Src activation, trigger signaling pathways 
mediated by ß-arrestins, i.e. full activation of Akt. Additionally, the impact of GRKs or second messenger kinases 
(i.e. PKCs) on the receptor phosphorylation and consequent ß-arrestin recruitment might be proposed as the 
missing link between G protein and ß-arrestins. Our data highlight the possibility that the functions of ß-arrestins 
may be pre-specified by GRK/PKC-receptor interaction. This is consistent with previous works on other GPCRs,, 
which demonstrate a requirement for GRKs to activate specific transducers as well as to affect transducer func-
tionality in a selective manner16,30. Thus, the patterning of receptor phosphorylation sites, barcode, could engen-
der subtle differences in ß-arrestin/receptor interactions that lead to divergent ß-arrestin-dependent signaling 
events.
One of the possible physiological implications of our data is that the signaling outcome of GHSR1a might be 
determined in a cell type specific manner by differential phosphorylation. For the M3-muscarinic receptor, for 
example, we have demonstrated that the pattern of receptor phosphorylation varies between different cell types 
in a manner that might contribute to cell type specific signaling17–20. The fact that we identify two distinct regions 
of phosphorylation on GHSR1a that contribute differentially to arrestin-dependent signaling means that differ-
ential cell type specific phosphorylation might result in different signaling outcomes. We are currently testing this 
hypothesis by determining if GHSR1a is differentially phosphorylated in different cell types. Ultimately, the fact 
that GHSR1a can direct functionality via different pathways unveils a tremendous potential for new approaches in 
developing therapeutics at this receptor particularly taking into account the physiological and pathophysiological 
effects in both neural and peripheral tissue.
Experimental Procedures
Materials. Human ghrelin was obtained from California Peptides (CA, US). Anti-Akt, anti-ERK1/2, anti-pA-
kt(S473) and anti-pERK1/2(T202/Y204) antibodies were from Cell Signaling Technology (MA, US). Anti-ß-
arrestin 1 antibody was obtained from BD Biosciences (CA, US). Anti-EGFP and anti-ß-arrestin 2 antibodies 
were from Abcam (Cambridge, UK). Secondary antibodies and enhanced chemiluminescence detection system 
were from GE-Amersham (Buckinghamshire, UK). Radioisotope [32P]-orthophosphate (specific activity 8500–
9120 Ci/mmol), were from PerkinElmer Life Sciences. Unless otherwise stated, all biochemical and reagents were 
from Sigma (Mo, US).
Cell culture. The human embryonic kidney (HEK) 293 wild-type (WT) cell line was maintained in 
DMEM (Lonza; Basilea, CH) supplemented with fetal bovine serum [FBS, 10% (v/v)], and 100 U/mL 
penicillin-streptomycin solution (100U/mL). The wild-type (WT), the ß-arrestin 1 knockout (ß-arrestin-1−/−) 
and the ß-arrestin 2 knockout (ß-arrestin-2−/−) murine embryonic fibroblast (MEF) cells, provided by Prof. 
Robert J. Lefkowitz (Duke University Medical Center, Durham, NC, US), were maintained in DMEM supple-
mented with 10% (v/v) FBS and 100 U/mL penicillin-streptomycin solution. The GC cell line was maintained 
routinely as a monolayer in complete DMEM medium supplemented with 15% (v/v) horse serum, 2.5% (v/v) FBS 
and 100 U/mL penicillin G-streptomycin solution. 3T3-L1 preadipocytes were maintained in DMEM containing 
10% fetal bovine serum (FBS), 100 U/mL penicillin-streptomycin solution. For 3T3-L1 adipocyte differentiation, 
the 2-day-postconfluent cells (day 0) were treated with 0.5 mM isobutylmethylxantine (IBMX), 25 μM dexameth-
asone (DEX), and 861 nM insulin or ghrelin in DMEM containing 10% FBS for 72 h. After 72 h, was renewed 
every 48 h with DMEM containing 10% FBS and either insulin or ghrelin (172 nM) until the cells were used. 
Cultures were incubated at 37 °C in a humidified atmosphere containing 5% CO2.
Plasmids, mutagenesis and cell transfection. The wild-type GHSR1a fused at its C terminus to 
enhanced green fluorescent protein (EGFP) (GHSR1a-WT) in pEFGP-N1 (Clontech, Palo Alto, CA, US) was 
provided by Prof. Catherine Llorens-Cortes (Institut National de la Sante et de la Recherche Medicale, College 
de France, Chaire de Medecine Experimentale, Paris, France). EGFP tagged GHSR1a receptor used in the pres-
ent work showed to have cellular location, endocytosis and G-protein associated signaling similar to the native 
GHSR1a protein31. Mutations to the GHSR1a sequence were incorporated using the QuikChange method 
(Stratagene, Cheshire, UK), and the identities of all plasmids generated were confirmed through sequencing. The 
cells were transiently transfected with the GHSR1a-WT and its three mutants [Double mutant (GHSR1a-DM): 
Thr350Ala, Ser349Ala; Triple mutant (GHSR1a-TM): Ser362Ala, Ser365Ala, Thr366Ala; and, Total mutant 
(GHSR1a -Total): Thr350Ala, Ser349Ala, Ser362Ala, Ser365Ala, Thr366Ala] using Lipofectamine 2000 (Life 
Technologies, Invitrogen; Gran Island, NY, US), according to the manufacturer’s instructions. The cell lines 
expressing the GHSR1a-WT and its three mutants were cultured as above described. Pure cell lines were selected 
on the basis of resistance to geneticin (G418; 500 μg/mL; maintenance antibiotic). Resistant cells were further 
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selected using flow-assisted cell sorting, after which they were maintained in complete DMEM, supplemented 
with G418.
ß-arrestin 1 tagged with red fluorescent protein (RFP; ß-arrestin 1-RFP) was provided by Prof. Robert 
J. Lefkowitz (Duke University Medical Center, Durham, NC, US) through Addgene (Cambridge, MA, US). 
ß-arrestin 2 tagged with m-cherry or Rluc at its C-terminus (ß-arrestin 2-mcherry) was generated by PROTEX 
(Protein Expression Laboratory) at the University of Leicester (http://www2.le.ac.uk/departments/biochemistry/
facilities/protex). Briefly, ß-arrestin 2 was amplified by PCR using primers, which removed the stop codon and 
was subcloned into pLeics-30 or pLeics-85 expression vectors. To generate the GHSR1a WT and three mutants 
fused to enhanced yellow fluorescent protein (eYFP; GHSR1a), receptors were amplified by PCR using primers 
which removed the stop codon and introduced a 5′ HinDIII and 3′ Kpn I restriction sites. The template for the 
reaction was GHSR1a WT in pcDNA3.1 vector. The resulting PCR products were subcloned into pcDNA3.1 
upstream of full-length eYFP to generate C-terminal eYFP fusion constructs. Mutations were introduced into 
the C-terminus of the resulting fusion protein using the QuikChange method (Stratagene, Cheshire, UK). Renilla 
luciferase-tagged ß-arrestin 1 (Rluc-ß-arrestin 1) was provided by Prof. Mark Scott (Institut Cochin, Paris, FR). 
All cellular assays involving transient transfections were only carried out if the transfection efficiency was 80% 
or higher.
[32P]Orthophosphate Labelling and GHSR1a Immunoprecipitation. GHSR1a-EGFP, 
GHSR1a-EGFP DM, GHSR1a-EGFP TM or GHSR1a-EGFP Total cell lines were plated in 6-well plates at 
200,000 cells/well 24 h before experimentation and serum starved overnight. For phosphorylation experiments, 
cells were washed three times with Krebs/HEPES buffer without phosphate [containing in mM: HEPES, 10 (pH 
7.4); NaCl, 118; CaCl2, 1.3; KCl, 4.3; MgSO4, 1.17; NaHCO3, 4.17; glucose, 11.7] and incubated in this buffer 
containing 100 μCi/mL [32P]orthophosphate for 1 h at 37 °C and 5% CO2. Cells were then stimulated with ghrelin 
(100 nM, 5 min) and immediately lysed by addition of lysis buffer [containing in mM: Tris/HCl, 20 (pH 7.4); 
NaCl, 150; and EDTA, 3; and supplemented with 1% (v/v) Nonidet P-40, and 0.5% (w/v) sodium deoxycholate]. 
GHSR1a was immunoprecipitated from the cleared lysates using GFP-trap (Chromotek; DE) following manu-
facturer’s instructions. The washed immunoprecipitates were separated by SDS-PAGE on two 10% gels. The first 
gel was dried, and radioactive bands were revealed using autoradiography film. The second gel was transferred 
to nitrocellulose membrane as loading control. The analysis was carried out using ImageJ software (National 
Institutes of Health, Bethesda, MD, US).
GHSR1a Receptor Purification and Mass Spectrometry. For GHSR1a purification, the 
GHSR1a-EGFP cell line was harvested (10 confluent T175 flasks), resuspended in Krebs/HEPES buffer and stim-
ulated with ghrelin (100 nM, 5 min). Membranes were then prepared and solubilized by addition of 5 mL of TE 
buffer plus a mixture of protease and phosphatase inhibitors (Roche Applied Science). After centrifugation at 
20,000 × g, the resulting supernatant was diluted 1:1 with PBS, and the receptor was then purified on GFP-trap 
(Chromotek, DE). After extensive washing with solubilization buffer containing 0.5% Nonidet P-40, the resin was 
resuspended in 2 × SDS-PAGE sample buffer. The sample was resolved by SDS-PAGE on 10% gels and stained 
with colloidal Coomassie Blue. Purified GHSR1a receptor was excised from the polyacrylamide and washed three 
times for 5 min with 50 mM ammonium bicarbonate. Reduction and alkylation of cysteines were performed by 
addition of 10 mM dithiothreitol (DTT) in 50 mM ammonium bicarbonate at 55 °C for 30 min followed by addi-
tion 100 mM iodoacetamide in 50 mM ammonium bicarbonate for 30 min in the dark. Gel slices were washed 
three times for 5 min with 50 mM ammonium bicarbonate containing 50% acetonitrile and incubated overnight 
at 37 °C in 50 mM ammonium bicarbonate containing 10% (v/v) acetonitrile and 1 μg of sequencing grade trypsin 
(Promega, Southampton, UK). After tryptic digestion, phosphopeptides were enriched using PHOS-SelectTM iron 
affinity resin.
LC-MS/MS was carried out on each sample using an LTQ OrbiTrap mass spectrometer (Applied Biosystems, 
Warrington, UK). Peptides resulting from in-gel digestion were loaded at a high flow rate onto a reverse-phase 
trapping column (0.3 mm inner diameter × 1 mm), containing 5 μm of C18 300 Å Acclaim PepMap media 
(Dionex, UK) and eluted through a reverse-phase capillary column (75 μm inner diameter × 150 mm) contain-
ing Symmetry C18 100 Å media (Waters) that was self-packed using a high pressure packing device (Proxeon 
Biosystems, Odense, Denmark). The output from the column was sprayed directly into the nanospray ion source 
of an LTQ Orbital mass spectrometer. The resulting spectra were searched against the UniProtKB/SwissProt data 
base using MASCOT software (Matrix Science Ltd.) with peptide tolerance set to 5 ppm and the MS/MS toler-
ance was set to 0.6 Da. Fixed modifications were set as carbamidomethyl cysteine with variable modifications of 
phosphoserine, phosphothreonine, phosphotyrosine, and oxidized methionine. The enzyme was set to trypsin/
proline, and up to two missed cleavages was allowed. Peptides with a Mascot score greater than 20 and where 
the probability (p) that the observed match was a random event was < 0.05 were included in the analysis. The 
spectra of peptides reported as being phosphorylated were interrogated manually to confirm the precise sites of 
phosphorylation.
GHSR1a/ß-arrestin Interaction Assays. A bioluminescence resonance energy transfer (BRET) assay was 
used to monitor interactions between GHSR1a and ß-arrestin. YFP tagged-GHSR1a-WT (YFP-GHSR1a-WT), 
YFP-GHSR1a-DM, YFP-GHSR1a-TM or YFP-GHSR1a-Total were co-transfected with Rluc-ß-arrestin 1 or 
Rluc-ß-arrestin 2 at a ratio of 4:1 using Lipofectamine 2000 (Life Technologies, Invitrogen, Gran Island, NY, US) 
following manufacturer’s indications. After 24 h incubation, cells were subcultured into poly-D-lysine-coated 
white 96-well microplates, incubated for a further 24 h prior to the assay and serum starved overnight. Cells 
were then washed with Hanks’ balanced salt solution and incubated in this buffer for 30 min prior to conducting 
the assay. To initiate the assay, the Rluc substrate coelenterazine (Life Technologies, Invitrogen; Gran Island, 
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NY, US) was added to a final concentration of 2.5 μM and incubated for 10 min at 37 °C before ghrelin was 
added. Following a further 5 min incubation, luminescence emissions at 535 and 475 nm were measured using a 
CLARIOstar (BMG Labtech; Offenburg, DE), and the BRET signal was presented as the 535/475 ratio multiplied 
by 1000 to yield the arbitrary milli-BRET units.
Immunoblot analysis. Serum-starved cells were stimulated with ghrelin (100 nM) for the indicated time 
period at 37 °C. The medium was then aspirated and the cells were lysed in ice-cold RIPA buffer supplemented 
with protein and phosphatase inhibitors. The solubilized lysates were transferred into centrifuge tubes and 
left at 4 °C for 15 min, then pre-cleared by centrifugation at 18,000 × g for 15 min at 4 °C. Protein concentra-
tion was evaluated with the QuantiPro BCA assay kit. Subsamples (same amount of protein) of each sample 
were separated by SDS-PAGE on 10% gels and transferred to nitrocellulose membranes. The immunoreactive 
bands were detected by enhanced chemiluminescence (Pierce ECL Western Blotting Substrate; Thermo Fisher 
Scientific, Pierce, Rockford, IL, US). The resulting protein bands were scanned and analyzed using ImageJ soft-
ware (National Institutes of Health, Bethesda, MD, US) and normalized for the corresponding loading controls.
Confocal Assays. For analysis of the endocytosis time course, HEK 293 cells on poly-D-lysine-coated cov-
erslips were transfected with the EGFP-tagged GHSR1a-WT, GHSR1a-DM, GHSR1a-TM or GHSR1a-Total. The 
cells were grown overnight in a humidified atmosphere of 95% air and 5% CO2 at 37 °C. The cells were prein-
cubated for 120 min at 37 °C with 90 μM cycloheximide in all experiments to prevent de novo protein synthesis. 
The cells were preincubated for 30 min at 4 °C in ice-cold Earle’s buffer [containing (in mM): 140 NaCl, 5 KCl, 
1.8 CaCl2, and 3.6 MgCl2 (pH 7.4); and, complemented with 0.2% BSA, 0.01% glucose, 90 μM cycloheximide, and 
0.8 mm of 1–10 phenanthrolene] in the presence/absence of ghrelin (100 nM). Internalization was promoted by 
placing the cells at 37 °C. The cells were then rinsed three times with ice-cold Earle’s buffer and subsequently fixed 
for 10 min with 4% paraformaldehyde dissolved in 0.1 mM phosphate-buffered saline [PBS (pH 7.4)]. The cells 
were rinsed again in cold Earle’s buffer, mounted using Vectashield (Vector Laboratories, Compiègne, France). To 
determine the interaction between the GHSR1a and ß-arrestins, the HEK 293 cells were cotransfected with the 
EGFP-tagged GHSR1a-WT, GHSR1a-DM, GHSR1a-TM or GHSR1a-Total and the corresponding RFP-tagged 
ß-arrestin 1 or m-cherry-tagged ß-arrestin 2 in a 1:1 ratio. For immunofluorescence analysis of ERK1/2 acti-
vation, the HEK 293 cells were transfected and cultured as indicated above. After ghrelin stimulation for the 
indicated times, the cells were fixed with 4% buffered paraformaldehyde-PBS for 15 min, washed, permeabilized 
(1% Triton X-100, 1% Tween 20 in PBS) for 30 min, and blocked with PBST (1% Triton X-100, 1% Tween 20, 5% 
heat-inactivated normal goat serum, 0.2% BSA in PBS) for 60 min and then incubated with anti-pERK1/2(T202/
Y204) antibody diluted in PBST (1:500) overnight at 4 °C. After three washes with PBS, cells were incubated 
with the secondary antibody (Alexa Fluor 594-conjugate goat anti-rabbit antibody) in PBST (1:1000) for 60 min 
at room temperature. DAPI was used to counterstain the cell nuclei (Invitrogen). Digital images of cell cul-
tures were acquired with a Leica TCS-SP5 spectral confocal microscope (Leica Microsystems; Heidelberg, DE). 
Quantification of PCC and MOC was developed using ImageJ software (National Institutes of Health, Bethesda, 
MD, US).
Proliferation assays. HEK 293 cell proliferation was determined using the BrdU incorporation-ELISA assay 
(Roche Applied Science; Mannheim, GE) following manufacturer’s instructions. Briefly, cells (10 × 103/well) were 
cultured in DMEM supplemented with ghrelin (100 nM) for 12 h and then were incubated with 10 mg/mL BrdU 
for 12 h before being fixed with FixDenat solution. The fixed cells were further treated with anti-BrdU-POD 
working solution, and rinsed with washing solution before substrate solution was added. The absorbance at 
370 nm (reference wavelength at 492 nm) was measured using an ELISA plate reader (Reader VersaMaxPLUS).
Quantification of lipid accumulation. The accumulated lipid droplets were stained with Oil Red O as 
previously described14. Briefly, the differentiated 3T3-L1 adipocytes cells were washed with PBS, fixed with for-
maldehyde solution and stained with Oil Red. For quantification, the cells were washed extensively with water to 
remove unbound dye, isopropanol was added to the stained culture plates, and analyzed using spectrophotometry 
at 520 nm.
Inositol 1-phosphate incorporation. Inositol 1-phosphate (IP1) incorporation was measured using 
IP-One HTRF® assay kit (Cisbio Assays, MA, USA) based on FRET technology. GHSR1a-WT, GHSR1a-DM, 
GHSR1a-TM or GHSR1a-Total cell lines were cultured into poly-D-lysine-coated 96-well microplates, incubated 
for a further 24 h prior to the assay and serum starved overnight. Cells were then treated with stimulation buffer 
plus ghrelin (100 nM, 1 h at 37 °C) and lysed by addition of lysis buffer for 30 min with shaking at 500 rpm. To 
initiate the assay 16 μL of lysate was transferred to a white 384 well plate and incubated with IP1-d2 conjugate and 
Anti-IP1 cryptate Tb-conjugate (1 h at 500 rpm). Fluorescence emissions at 665 and 620 nm were measured using 
a CLARIOstar (BMG Labtech; Offenburg, DE).
GH assay. Murine GH was measured by a rat/mouse GH ELISA (EMD Millipore, Billerica, Massachusetts, 
USA) in medium collected from the GC cultures, post-transfected with siRNAs according to the manufacture’s 
instructions. GH levels were analyzed in quadruplicate.
Small interfering RNA (siRNA) silencing of gene expression and transfection. Chemically syn-
thesized double-stranded siRNA duplexes for ß-arrestin 1 and ß-arrestin 2 were selected from ON-TARGET 
plus SMART pool siRNA from Thermo Fisher Scientific (Dharmacon, Lafayette, CO, US; mouse ß-arrestin 1 
(5′ → 3′): ACGGGAAGCUCAAGCAUGA; UCAUAGAGCUUGACACCAA; GGAGAACCCAUCAGCGUUA; 
UGGAUAAGGAGAUCUAUUA; human ß-arrestin 1 (5′ → 3′): UGGAUAAGGAGAUCUAUUA, AUGGAAAGC 
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UCACCGUCUA,GAACUGCCCUUCACCCUAA,GAACGAGACGCCAGUAGAU; mouse ß-arrestin 2 
(5′ → 3′): GUGCCAAAACAAUAGAAGA; AUACCAACCUCAUCGAAUU;CUACUUGAAGGACCGGA 
AA;GGGCCUGUCUUUCCGCAAA; human ß-arrestin 2(5′→ 3′): C GA ACAAGAUGACCAGGUA,CGGCG
UAGACUUUGAGAUU,GGGCUUGUCCUUCCGCAAA,UAGAUCACCUGGACAAAGU. An ON-TARGET 
plus Non-targeting siRNA was used as a control for all siRNA experiments. The cells were transfected with 
Lipofectamine 2000 (Life Technologies, Invitrogen, Gran Island, NY, US) according to the manufacture’s instruc-
tions. Based on the short half-life of these siRNAs during adipocyte differentiation (~4 days), the confluent 
3T3-L1 cells were transfected after the induction of adipogenesis [transfection in terminal adipocyte differenti-
ation: treatment with 0.5 mM IBMX, 25 μM DEX, and 861 nM ghrelin in DMEM containing 10% FBS for 3 days 
for induction of adipogenesis, and then siRNA transfection and maintenance in DMEM containing 10% FBS 
supplemented with 172 nM ghrelin for 3 days as previously described14.
Data analysis. All values are presented as mean ± standard error of the mean (SEM). Student t test were per-
formed to assess the statistical significance of 2-way analysis. For multiple comparisons, ANOVA was employed. 
p < 0.05 was considered as statistically significant (*,#).
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